V
Vanqua Bio
Biopharmaceutical innovations targeting neurodegenerative diseases with advanced drug development and cutting-edge assays
About Vanqua Bio
Founded in 2019, Vanqua Bio is a biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases. The company focuses on creating innovative therapies by combining advanced insights into critical neuronal cell pathways with cutting-edge assays. Vanqua Bio's lead program targets glucocerebrosidase (GCase) as a potential treatment for Parkinson's Disease (PD) and all forms of Gaucher Disease (GD).
Vanqua Bio serves patients suffering from neurodegenerative disorders, including PD, GD, Alzheimer's Disease (AD), and related neurological conditions. The company operates in the biopharmaceutical market, leveraging its scientific expertise, creativity, and experience to develop transformative medicines.
The business model of Vanqua Bio revolves around drug discovery and development, aiming to bring new therapies to market. The company generates revenue through the development and potential commercialization of its drug candidates. By assembling a world-class team of scientists, board members, and advisors with proven capabilities, Vanqua Bio is well-positioned to advance molecules that could become transformative medicines.
Vanqua Bio offers a comprehensive compensation package to its employees, including competitive base salaries, company ownership, and various benefits such as medical, dental, vision, 401k, life insurance, and disability coverage. The company also engages in strategic collaborations to enhance its drug development efforts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Chicago, United States
- Employees
- 36
- Open positions
- 1
- Dealroom signal
- 47.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Disease, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2024 | $45M | $180M | Undisclosed | ↗ |
| LATE VCOther financing | Feb 2024 | $45M | $425M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Vanqua Bio is 4.1K monthly website visits, down 10.9% over the last three months. Vanqua Bio's team grew 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Silverstein Foundation
Series A4 investors entered at this stage
Osage University Partners
OrbiMed
Citadel
Eli Lilly
Other known investors1 additional known investor
Northwestern University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vanqua Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vanqua Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.